AMRX Amneal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSE: AMRX

Price (delayed)

$1.33

Market cap

$403.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.86

Enterprise value

$3.21B

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in ...

Highlights
The company's gross profit rose by 7% QoQ and by 2% YoY
AMRX's revenue is up by 6% year-on-year and by 3.4% since the previous quarter
AMRX's quick ratio is down by 24% YoY but it is up by 16% from the previous quarter
AMRX's gross margin is down by 3.3% YoY but it is up by 3.2% from the previous quarter
Amneal Pharmaceuticals's equity has decreased by 17% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amneal.com
Peers: OCUP

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
303.62M
Market cap
$403.81M
Enterprise value
$3.21B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
0.09
EV/EBIT
91.68
EV/EBITDA
11.68
EV/Sales
1.45
Earnings
Revenue
$2.21B
EBIT
$35.05M
EBITDA
$275.23M
Free cash flow
$16.31M
Per share
EPS
-$0.86
Free cash flow per share
$0.11
Book value per share
$0.98
Revenue per share
$14.66
TBVPS
$13.94
Balance sheet
Total assets
$3.8B
Total liabilities
$3.62B
Debt
$2.85B
Equity
$298.42M
Working capital
$659.02M
Liquidity
Debt to equity
9.53
Current ratio
1.88
Quick ratio
1.03
Net debt/EBITDA
10.21
Margins
EBITDA margin
12.4%
Gross margin
35.5%
Net margin
-5.9%
Operating margin
-4.3%
Efficiency
Return on assets
-3.3%
Return on equity
-41%
Return on invested capital
0.9%
Return on capital employed
1.2%
Return on sales
1.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
1.53%
1 week
-6.99%
1 month
-38.99%
1 year
-67.32%
YTD
-33.17%
QTD
-33.17%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.21B
Gross profit
$784.71M
Operating income
-$96.11M
Net income
-$129.99M
Gross margin
35.5%
Net margin
-5.9%
The company's operating income has shrunk by 161% YoY but it rose by 17% QoQ
The operating margin has dropped by 157% year-on-year but it is up by 20% since the previous quarter
The company's gross profit rose by 7% QoQ and by 2% YoY
AMRX's revenue is up by 6% year-on-year and by 3.4% since the previous quarter

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.35
P/S
0.09
EV/EBIT
91.68
EV/EBITDA
11.68
EV/Sales
1.45
The price to book (P/B) is 75% lower than the 5-year quarterly average of 5.3 and 50% lower than the last 4 quarters average of 2.7
Amneal Pharmaceuticals's equity has decreased by 17% YoY
The price to sales (P/S) is 89% lower than the 5-year quarterly average of 0.8 and 55% lower than the last 4 quarters average of 0.2
AMRX's revenue is up by 6% year-on-year and by 3.4% since the previous quarter

Efficiency

How efficient is Amneal Pharmaceuticals business performance
AMRX's ROS has dropped by 79% year-on-year but it is up by 33% since the previous quarter
AMRX's ROIC has plunged by 77% YoY but it has soared by 50% from the previous quarter
Amneal Pharmaceuticals's return on equity has decreased by 3.3% QoQ
The company's return on assets rose by 2.9% QoQ

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 5% greater than its total liabilities
AMRX's quick ratio is down by 24% YoY but it is up by 16% from the previous quarter
The company's current ratio fell by 16% YoY but it rose by 8% QoQ
The company's debt to equity rose by 19% YoY
Amneal Pharmaceuticals's equity has decreased by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.